JGUA
GSK icon

John G. Ullman & Associates’s GSK GSK Stock Holding History

John G. Ullman & Associates’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.01M Sell
72,610
-6,330
-8% -$343K 0.53% 60
2025
Q4 		$3.87M Sell
78,940
-2,020
-2% -$94.2K 0.52% 63
2025
Q3 		$3.49M Sell
80,960
-1,140
-1% -$44.5K 0.47% 64
2025
Q2 		$3.15M Sell
82,100
-1,770
-2% -$67.6K 0.47% 67
2025
Q1 		$3.25M Sell
83,870
-1,160
-1% -$42.5K 0.5% 67
2024
Q4 		$2.88M Buy
85,030
+910
+1% +$32.8K 0.42% 74
2024
Q3 		$3.44M Sell
84,120
-1,660
-2% -$67.9K 0.49% 67
2024
Q2 		$3.3M Sell
85,780
-680
-0.8% -$28.6K 0.5% 62
2024
Q1 		$3.71M Sell
86,460
-2,280
-3% -$94K 0.57% 55
2023
Q4 		$3.29M Buy
88,740
+12,160
+16% +$437K 0.52% 61
2023
Q3 		$2.78M Sell
76,580
-1,400
-2% -$49.7K 0.45% 66
2023
Q2 		$2.78M Buy
77,980
+560
+0.7% +$20.1K 0.43% 69
2023
Q1 		$2.75M Buy
77,420
+6,410
+9% +$224K 0.43% 62
2022
Q4 		$2.5M Sell
71,010
-156,335
-69% -$5.21M 0.4% 62
2022
Q3 		$6.69M Sell
227,345
-66,561
-23% -$2.52M 1.17% 27
2022
Q2 		$16M Sell
293,906
-2,240
-0.8% -$124K 2.57% 9
2022
Q1 		$16.1M Sell
296,146
-6,620
-2% -$360K 2.23% 11
2021
Q4 		$16.7M Sell
302,766
-15,360
-5% -$799K 2.3% 10
2021
Q3 		$15.2M Sell
318,126
-101,452
-24% -$5.1M 2.07% 14
2021
Q2 		$20.9M Sell
419,578
-2,960
-0.7% -$142K 2.72% 10
2021
Q1 		$18.9M Buy
422,538
+94,765
+29% +$4.3M 2.53% 10
2020
Q4 		$15.1M Buy
327,773
+1,399
+0.4% +$64.3K 2.34% 11
2020
Q3 		$15.4M Sell
326,374
-5,546
-2% -$278K 3.18% 6
2020
Q2 		$16.9M Sell
331,920
-9,220
-3% -$473K 4.13% 5
2020
Q1 		$16.2M Buy
341,140
+91,640
+37% +$4.89M 4.29% 5
2019
Q4 		$14.7M Sell
249,500
-5,740
-2% -$319K 2.52% 8
2019
Q3 		$13.6M Buy
255,240
+6,260
+3% +$322K 2.47% 9
2019
Q2 		$12.5M Buy
248,980
+51,780
+26% +$2.6M 2.19% 11
2019
Q1 		$10.3M Buy
197,200
+36,640
+23% +$1.83M 1.87% 19
2018
Q4 		$7.67M Buy
160,560
+74,532
+87% +$3.67M 1.55% 24
2018
Q3 		$4.32M Buy
86,028
+28,160
+49% +$1.43M 0.79% 44
2018
Q2 		$2.92M Sell
57,868
-3,040
-5% -$153K 0.55% 54
2018
Q1 		$2.98M Buy
60,908
+3,180
+6% +$148K 0.58% 54
2017
Q4 		$2.56M Sell
57,728
-86,238
-60% -$3.98M 0.51% 55
2017
Q3 		$7.31M Buy
143,966
+32,640
+29% +$1.66M 1.42% 27
2017
Q2 		$6M Buy
111,326
+9,416
+9% +$502K 1.19% 32
2017
Q1 		$5.37M Buy
101,910
+4,592
+5% +$233K 1.11% 34
2016
Q4 		$4.68M Sell
97,318
-40,748
-30% -$2.01M 0.98% 39
2016
Q3 		$7.44M Sell
138,066
-8,008
-5% -$439K 1.53% 20
2016
Q2 		$7.91M Sell
146,074
-9,426
-6% -$497K 1.63% 17
2016
Q1 		$7.88M Sell
155,500
-24,864
-14% -$1.24M 1.85% 17
2015
Q4 		$9.1M Sell
180,364
-28,280
-14% -$1.44M 2.01% 14
2015
Q3 		$10M Sell
208,644
-7,336
-3% -$382K 2.38% 10
2015
Q2 		$11.2M Buy
215,980
+9,420
+5% +$530K 2.12% 9
2015
Q1 		$11.9M Buy
206,560
+17,656
+9% +$1.01M 2.26% 10
2014
Q4 		$10.1M Buy
188,904
+11,548
+7% +$646K 1.9% 13
2014
Q3 		$10.2M Buy
177,356
+12,472
+8% +$765K 1.96% 13
2014
Q2 		$11M Buy
164,884
+7,595
+5% +$514K 2.01% 12
2014
Q1 		$10.5M Buy
157,289
+5,004
+3% +$338K 1.95% 14
2013
Q4 		$10.2M Sell
152,285
-2,899
-2% -$188K 1.94% 13
2013
Q3 		$9.73M Sell
155,184
-1,312
-0.8% -$84.5K 1.98% 11
2013
Q2 		$9.78M Buy
+156,496
New +$9.93M 2.04% 10

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

John G. Ullman & Associates's GSK Position: Q1 2026 in Review

John G. Ullman & Associates reduced its GSK (GSK) stake by 8% in Q1 2026, selling an estimated $343K and leaving 72,610 shares worth $4.01M. The position accounts for 0.53% of the portfolio, ranked #60.

John G. Ullman & Associates first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $20.9M in Q2 2021. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • John G. Ullman & Associates held 72,610 shares of GSK worth $4.01M as of Q1 2026.
  • John G. Ullman & Associates sold 6,330 GSK shares in Q1 2026, an estimated $343K.
  • GSK made up 0.53% of John G. Ullman & Associates's portfolio in Q1 2026, its #60 holding.
  • John G. Ullman & Associates first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
  • John G. Ullman & Associates's GSK position peaked at $20.9M in Q2 2021.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on John G. Ullman & Associates's 13F filing for Q1 2026, filed 6 May 2026.